In her new job, Visconti is liable for the creative agency’s promoting intelligence expert services as well as the teams that contribute to improving client conclusion-creating and “optimizing the influence of customer advertising strategies.”
Visconti is a electronic internet marketing and analytics veteran, owning labored in the area since 2007. She has previously held roles at BioteMedical, a bioidentical hormone replacement therapies service provider, as very well as Belo + Enterprise, a consumer agency. She also at present serves as a professor of electronic advertising and marketing and analytics at Southern Methodist College.
“Rebecca brings a wealth of specialized and analytical encounter to her management job at AbelsonTaylor, which is completely necessary in creating effective advertising campaigns in today’s knowledge-intensive environment,” Christopher Dimmock, AbelsonTaylor’s SVP of integrated strategy, reported in a statement. “But she also delivers powerful advertising, team-building, and collaboration skills and the skill to use truth-centered details to drive measurable company good results.”
For her aspect, Visconti stated she is thrilled to be doing the job with AbelsonTaylor’s team of info architects and information visualization professionals to progress the organization’s mission ahead.
“This is an exciting time to be in health care advertising and marketing and I’m happy to be section of the groundbreaking function getting carried out at AbelsonTaylor,” she said in a statement.
Visconti’s appointment is the most current in a collection of staff moves that the 2022 MM+M Agency 100 honoree has made this 12 months.
In July, AbelsonTaylor promoted Amy Restko, who has been with the organization considering the fact that 2016, to account planning director.
All through the spring, the company also announced the retain the services of of Jeremy Vannatta as VP, account director. In this job, Vannatta oversees AbelsonTaylor’s oncology clientele and experiences to EVP and director of consumer expert services Lynnette Hunter.
The company has been on a steady trajectory amid substantial sector-large disruptions linked to the COVID-19 pandemic.
In 2021, profits rose 13%, to $64.8 million, up from $57.2 million in 2020. In the meantime, the company secured assignments from Coherus BioSciences, Arcutis Biotherapeutics, Cooper-Surgical and Aerovate Therapeutics.